Introducing Thomas Gidoin as the New Chief Financial Officer
OSE Immunotherapeutics SA (PARIS:OSE) is excited to announce the appointment of Thomas Gidoin as its new Chief Financial Officer. With more than 15 years of extensive experience in capital markets and financial strategies, Thomas is set to become a key asset to the executive team, driving the company's financial initiatives forward.
Expertise in Biopharma Finance
Before joining OSE Immunotherapeutics, Thomas held the position of Chief Financial Officer at Advesya, a Franco-Swiss biotech firm specializing in oncology and autoimmune diseases. His previous tenure includes an impressive eight years at GenSight Biologics, a company known for developing innovative gene therapies targeting neurodegenerative retinal ailments. During his time there, he was instrumental in leading the company’s financing journey, from initial funding rounds to a successful public listing on Euronext Paris.
A Diverse Background
In addition to his experience with Advesya and GenSight, Thomas also worked as Vice President of Finance at DBV Technologies. There, he played a vital role in corporate finance, contributing to significant public offerings and private placements. His experience expands beyond biotech; Thomas previously served as Northern Europe Business Controller at PregLem and held various financial roles at Ipsen.
Vision for Financial Leadership
Thomas Gidoin is equipped with master’s degrees in international finance from ESGF Paris and in international management from NEOMA Business School. His solid educational foundation complements his vast experience and reinforces the strategic financial expertise he brings to OSE.
Stepping Into a New Era
In this pivotal role, he succeeds Anne-Laure Autret-Cornet, setting the stage for a dynamic shift in the company's financial leadership. Nicolas Poirier, the CEO of OSE Immunotherapeutics, shared his enthusiasm about the strategic advantage Thomas's experience offers at a critical time for the organization. "His capabilities will support our efforts to enhance two late-stage assets while maximizing our innovative research platform," he stated.
Commitment to Innovation
Thomas expressed his excitement about joining OSE Immunotherapeutics, recognizing the company’s potential to create significant long-term value through its robust pipeline of oncology and inflammation-focused therapeutics. He looks forward to collaborating with the leadership team to leverage the innovative strengths of OSE, aiming to unlock its fullest potential.
About OSE Immunotherapeutics
OSE Immunotherapeutics is at the forefront of developing pioneering immuno-oncology and immuno-inflammation therapies, dedicated to addressing critical patient needs. The company partners with esteemed academic institutions and pharmaceutical entities to progress transformative medicines designed for individuals battling serious diseases.
Exploring Future Projects
With a commitment to impactful drug development, OSE Immunotherapeutics focuses on creating treatments that significantly improve patient outcomes. The team combines their resources and expertise in order to innovate effectively in a rapidly evolving biopharma landscape.
Frequently Asked Questions
Who is Thomas Gidoin?
Thomas Gidoin is the newly appointed Chief Financial Officer of OSE Immunotherapeutics, bringing over 15 years of experience in the financial sector.
What companies did Thomas Gidoin work for before OSE Immunotherapeutics?
Prior to joining OSE, Thomas served as CFO at Advesya and spent eight years at GenSight Biologics. He also held notable positions at DBV Technologies and Ipsen.
What is OSE Immunotherapeutics' focus?
OSE Immunotherapeutics concentrates on developing innovative immuno-oncology and immuno-inflammation assets aimed at meeting patient needs.
What educational background does Thomas Gidoin have?
Thomas holds master's degrees in international finance from ESGF Paris and international management from NEOMA Business School.
What new role is Thomas Gidoin stepping into?
Thomas is stepping into the role of Chief Financial Officer, succeeding Anne-Laure Autret-Cornet, to lead the company’s financial strategies.
